Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of “Reduce” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have earned an average recommendation of “Reduce” from the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and six have assigned a hold recommendation to the company.

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th.

Bayer Aktiengesellschaft Trading Up 1.6 %

OTCMKTS:BAYRY opened at $5.05 on Monday. Bayer Aktiengesellschaft has a fifty-two week low of $4.94 and a fifty-two week high of $9.79. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04. The company has a 50 day moving average price of $6.89 and a 200 day moving average price of $7.25.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.46%. The firm had revenue of $10.96 billion during the quarter. As a group, equities analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.